Normalize with Mytesi

1 in 5 people living with HIV suffer from chronic diarrhea.
Mytesi is the only FDA-approved treatment that can provide sustained relief from noninfectious diarrhea.1

Key Benefits

Works long-term

Mytesi can effectively reduce noninfectious diarrhea. It is a non-opiate derivative and has a very low risk of causing constipation.

No significant drug interactions

Mytesi is not systemically absorbed into the bloodstream, and it does not interact with other medications.

Indicated for people living with HIV

Mytesi does not affect viral load, and it is effective and safe to use long-term to provide symptomatic relief of HIV-related diarrhea.

9 of 10 people living with HIV had fewer watery stools after 20 weeks of Mytesi treatment than they did before the study.2

Normalizing Your Gut


Chloride ion (Cl) channels in the gastrointestinal (GI) tract maintain a balance of salts—including chloride ions—and water that allows normal stool formation.



Chloride ion (salt)

Chloride ion channel

Improper function of ion channels leads to an excess of salts and water within the GI tract, disrupting the normal balance and resulting in diarrhea.

Mytesi restores the balance of salts and water in the GI tract by normalizing improperly functioning chloride ion (Cl) channels.

After 3-4 weeks, Mytesi can reduce the severity of watery bowel movements and provide sustained long term relief 1. In nonclincal studies, crofelemer, the active ingredient in Mytesi, does not slow down gut motility and is therefore less likely to cause constipation.

Is Mytesi Right for Me?

  • I am living with HIV
  • I am taking ART
  • I want relief from my
    noninfectious diarrhea
Save on Mytesi

Learn ways to save

Discuss with your doctor

Talk with your provider
about Mytesi

How Mytesi Works

Learn about how Mytesi helps
with normalizing your gut.

  1. Gehrig M, Clay P, Perry R, et al. Actual versus perceived use of pharmacokinetic (primarily absorption) influential OTC agents and ART tolerability in a nationwide matched cohort of HIV patients and their healthcare providers. Poster abstract presented at: ID Week 2016; October 26-30, 2016; New Orleans, LA.
  2. MacArthur RD, Clay P, Blick G, et al. Long-Term Crofelemer Provides Clinically Relevant Reductions in HIV-Related Diarrhea. Poster presented at: 9th IAS Conference on HIV Science (IAS 2017); 2017 July 23-26; Paris, France.